Curis (NASDAQ:CRIS) Upgraded to Hold at Zacks Research

Curis (NASDAQ:CRIS) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Wednesday, Zacks reports.

CRIS has been the subject of several other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of Curis in a research note on Monday, August 17th. Finally, Wall Street Zen raised Curis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 22nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Curis has a consensus rating of “Hold” and a consensus price target of $43.00.

Curis Price Performance

Shares of CRIS stock opened at $1.16 on Wednesday. The firm has a 50-day moving average of $3.35 and a 200-day moving average of $9.20. The company has a market cap of $2.42 million, a P/E ratio of -0.08 and a beta of 3.01. Curis has a one year low of $1.11 and a one year high of $39.00.

Curis (NASDAQ:CRIS) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($4.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.95) by $2.93. Curis had a negative net margin of 80.29% and a negative return on equity of 2,365.94%. As a group, research analysts expect that Curis will post -24.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Curis

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC grew its position in Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 10,586 shares during the period. XTX Topco Ltd bought a new stake in Curis in the fourth quarter worth about $26,000. Focused Wealth Management Inc bought a new stake in Curis in the second quarter worth about $26,000. BlackRock Inc. purchased a new position in Curis in the second quarter valued at about $28,000. Finally, Squarepoint Ops LLC boosted its stake in Curis by 46.2% in the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 27,343 shares during the last quarter. 29.97% of the stock is owned by hedge funds and other institutional investors.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.